GET DAILY SIGNALSTvardi Therapeutics (TVRD): What the $10 Analyst Target Means for the Stock
Key Takeaways
- The central $10 stock price target used here is the arithmetic mean of seven verified analyst targets, rounded from roughly $9.57 for readability.
- The verified targets span a wide $3 to $14 range, reflecting deep disagreement among analysts about Tvardi Therapeutics (TVRD).
- With shares trading near $1.42, reaching $10 would require upside of roughly 600%—a very large move for a micro-cap biopharmaceutical company.
- Bullish analysts cite positive early data for oral STAT3 inhibitors TTI-101 and TTI-109, while the most cautious view assigns just a $3 target.
- The strongest risks are clinical-trial execution, recurring cash needs, and a share price that has fallen more than 60% over the past year.
- Readers can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages for more detail.
Analyst Price Targets and Consensus View
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral, small-molecule inhibitors of STAT3 (Signal Transducer and Activator of Transcription 3) to treat fibrosis-driven and inflammatory diseases. Its lead candidates are TTI-101 and TTI-109.
Seven current, attributable analyst price targets were reviewed for this analysis. They are: Barclays at $3 (Underweight), Chardan at $8, H.C. Wainwright at $9, Raymond James at $10, JonesTrading at $10, Piper Sandler at $13, and Lucid Capital at $14. The arithmetic mean of these seven figures is approximately $9.57, rounded here to a clean $10 central target.
The gap between the low ($3) and high ($14) targets is unusually wide. Bulls emphasize encouraging early signals for TTI-109, including evidence described as placebo-like gastrointestinal tolerability, which drove upgrades at Piper Sandler (to Overweight, target raised from $3 to $13) and Raymond James (to Outperform at $10). Lucid Capital lifted its target from $6 to $14. The cautious view, reflected in Barclays' downgrade to Underweight at $3 from $4, underscores execution and financing risk for a pre-revenue company. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
TVRD trades near $1.42, giving the company a market capitalization of only about $19 million. Reaching $10 would require an advance of roughly 600%, a very large move by any standard and one that is far above the stock's 52-week high of $5.69.
A path toward the target would likely depend on additional positive clinical data, progress toward pivotal trials or partnerships, and a sharp re-rating of a stock that has lost more than 60% of its value over the past year. Because Tvardi reports no meaningful revenue, the investment case rests almost entirely on scientific milestones rather than earnings or sales growth.
What Could Support a Move Toward the Target
- Positive early data for TTI-101 in hepatocellular carcinoma and for TTI-109, which analysts described as showing placebo-like gastrointestinal tolerability.
- A differentiated oral, small-molecule approach to inhibiting STAT3, a validated but historically difficult drug target.
- Recent upgrades and target increases from Piper Sandler, Raymond James, and Lucid Capital.
- A low share count and micro-cap valuation that could amplify upside if clinical catalysts land favorably.
What Could Prevent the Target From Being Reached
- Clinical-trial failure or safety concerns, which remain the dominant risk for any early-stage biotech.
- Recurring capital needs and potential share dilution for a company with minimal cash-generating ability.
- A sustained downtrend, with the stock already down more than 60% over the past year.
- A very wide analyst range—including a $3 target from Barclays—indicating genuine uncertainty about the science.
Technical Levels and Market Structure
The stock's 52-week range of $0.77 to $5.69 frames the technical picture. The $10 target sits far above the prior high, meaning it is not anchored to any established resistance level. On the downside, the $1 psychological level and the $0.77 low are the key areas to watch. The long-term trend structure remains firmly negative, so any durable move higher would likely first require the stock to reclaim and hold levels well above its recent trading range. From what I see, tools like Tickeron’s AI Trend Prediction Engine can help flag when momentum starts to shift in names like this.
Time Horizon and What Investors Should Monitor
Analyst targets typically reflect a research horizon of roughly 12 months, though individual assumptions vary. For Tvardi, the most important upcoming items are clinical data readouts for TTI-101 and TTI-109, quarterly results, any financing or partnership announcements, and analyst target revisions. Because the company is pre-revenue, regulatory and trial milestones matter more than conventional earnings metrics. I’m watching this closely because data readouts can move the stock quickly in either direction.
Final Assessment
The central $10 target reflects the average of seven verified analyst targets, not a guarantee of future performance. With shares near $1.42, the required move of roughly 600% is very large, and the wide $3-to-$14 analyst range shows that even professionals disagree sharply on Tvardi's prospects. Support comes from early clinical data and recent upgrades, while the principal obstacles are trial risk, cash needs, and a deeply negative long-term trend. Investors should monitor data readouts, financing activity, and analyst revisions rather than treat the target as a forecast.
Using AI Daily Buy/Sell Signals in Practice
In my research process, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to track momentum shifts across volatile names. The system scans thousands of stocks daily and flags Buy, Sell, or Hold ideas based on technical and market data. For a catalyst-driven micro-cap like Tvardi, it offers an additional layer of monitoring that complements fundamental work without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
TVRD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TVRD turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 32 of 36 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TVRD as a result. In 64 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +64.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVRD advanced for three days, in 185 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for TVRD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 24 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 55 cases where TVRD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
TVRD moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TVRD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TVRD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (3.498). P/E Ratio (-0.334) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. TVRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement